In the News

Traveling with cancer can be done, even if you’re in active treatment. Plan ahead so that you can fully enjoy your vacation.

Feelings of guilt are common after surviving cancer, but MSK offers many support services that can help patients feel better.

Meet a former NYPD officer who is battling a vicious enemy - ovarian cancer - with support from her new wife.

Learn how nurses at MSK also engage in cancer research projects designed to help improve patients’ treatment, symptoms, or experience.

Discover how current and former Memorial Sloan Kettering pediatric cancer patients closed out the end of the school year.

MSK physician Carol Brown spoke about cancer disparities at The US State of Women Summit organized by the White House. Learn how she and MSK are leading the way in addressing this issue.

Learn more about olaratumab, a promising drug that has been shown to extend survival for people with advanced soft tissue sarcoma — particularly leiomyosarcoma — by nearly a year in a phase II clinical trial.

A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email [email protected].

In case you missed it, here’s a recap of Monday’s highlights from the American Society of Clinical Oncology annual meeting.

Couldn’t be at ASCO this year? Read highlights from the first half of the meeting.